ARIKAYCE KIT Drug Patent Profile

When do Arikayce Kit patents expire, and what generic alternatives are available?

Arikayce Kit is a drug marketed by Insmed Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has one hundred and fourteen patent family members in twenty-six countries.

The generic ingredient in ARIKAYCE KIT is amikacin sulfate. There are fifteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the amikacin sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arikayce Kit

A generic version of ARIKAYCE KIT was approved as amikacin sulfate by MEITHEAL on September 28^th, 1993.

Summary for ARIKAYCE KIT

International Patents:	114
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARIKAYCE KIT
DailyMed Link:	ARIKAYCE KIT at DailyMed

Recent Clinical Trials for ARIKAYCE KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
APHM - Nord	PHASE2
CH Mulhouse	PHASE2
Hôpital Saint Joseph	PHASE2

See all ARIKAYCE KIT clinical trials

Pharmacology for ARIKAYCE KIT

Drug Class

Aminoglycoside Antibacterial

US Patents and Regulatory Information for ARIKAYCE KIT

ARIKAYCE KIT is protected by thirteen US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes			Y
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018		RX	Yes	Yes			Y

Expired US Patents for ARIKAYCE KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018
Insmed Inc	ARIKAYCE KIT	amikacin sulfate	SUSPENSION, LIPOSOMAL;INHALATION	207356-001	Sep 28, 2018

International Patents for ARIKAYCE KIT

See the table below for patents covering ARIKAYCE KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015258947
Australia	2020204530
Brazil	112016026699
Canada	2949078
China	106535877
Cyprus	1122129
Cyprus	1123411

ARIKAYCE KIT (amikacin inhalation) Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Exclusivity, Competitive Pressure, and Revenue Outlook

Last updated: June 3, 2026

Executive summary

• ARIKAYCE KIT (amikacin inhalation solution; liposomal nebulized delivery) is a niche, high-acuity therapy positioned for treatment-refractory Mycobacterium avium complex (MAC) lung disease. Demand is constrained by narrow indication, high per-patient regimen cost, and substitution risk from guideline shifts and competing MAC regimens.
• Financial trajectory has been shaped by (1) uptake after label expansion and payer acceptance, (2) industry-wide channel inventory swings typical in specialty respiratory drugs, and (3) persistent competitive pressure from non-ARIKAYCE MAC multidrug regimens and emerging inhaled/off-label approaches rather than direct “same molecule” inhaled comparators.
• Near-to-mid horizon revenue is driven more by payer coverage breadth, nebulizer adherence economics, and persistence than by broad population growth. Outcomes-based retention and clinician willingness to escalate to inhaled amikacin are the main upside levers.

What is ARIKAYCE KIT used for and how does that shape demand?

ARIKAYCE KIT is used for Mycobacterium avium complex (MAC) lung disease in patients with refractory disease. The commercial model is therefore inherently limited: MAC prevalence is not small, but the treatable, label-concordant segment that needs inhaled amikacin is smaller, and treatment is long-duration.

Key demand constraints

• Eligibility bottlenecks: label-concordant “refractory” or treatment-intolerant phenotypes reduce the addressable pool.
• Regimen complexity: ARIKAYCE is administered via nebulization and is typically used as part of combination antibiotic therapy, raising adherence friction.
• Treatment duration: MAC management can extend for years; discontinuation risk is meaningful when sputum conversion is delayed.

How does patient adherence and administration economics impact sales?

• ARIKAYCE KIT is a kit-based product designed for repeated dosing cycles. Specialty pharmacy workflows, nebulizer utilization, and patient training determine real-world persistence.
• Reimbursement structures that require prior authorization and documentation of refractory disease can slow initiation and compress growth in new lines of therapy.

What MAC guideline dynamics influence ARIKAYCE kit utilization?

MAC care pathways have trended toward multidrug regimens with individualized escalation. That structure tends to keep ARIKAYCE usage concentrated in patients not responding to standard combinations.

How is ARIKAYCE priced and reimbursed, and what does that do to affordability and uptake?

ARIKAYCE’s market dynamics depend on specialty drug pricing plus payer controls common to orphan-like niches: prior authorization, step therapy, and medical-necessity criteria built around culture results and refractory documentation.

Commercial drivers of coverage

• Payer willingness to cover inhaled amikacin when injectable/standard regimens fail.
• Evidence requirements: documentation of inadequate response, intolerance, or persistent positive cultures.

What payer mechanisms most affect ARIKAYCE revenue growth?

• Prior authorization throughput: delays at the administrative layer can reduce net patient starts even when demand exists clinically.
• Pharmacy benefit design: placement in specialty tiers influences copays and patient retention.
• Contracting with large PBMs: contract terms can determine whether ARIKAYCE wins formulary status in key regional plans.

What market dynamics are pushing ARIKAYCE KIT demand up or down?

ARIKAYCE’s demand is primarily shaped by clinical escalation patterns in MAC and by competitive substitution away from inhaled amikacin when clinicians believe standard regimens or alternative strategies are sufficient.

Uptake accelerants

• Continued clinician adoption where refractory disease management supports inhaled amikacin escalation.
• Enhanced payer coverage and reduced administrative friction.
• Persistence improvements through patient support programs and nebulizer coaching.

Downside risks

• Increased preference for intensified multidrug regimens rather than adding or keeping inhaled amikacin when outcomes are slow.
• Inventory volatility among specialty distributors and channels that can distort quarterly sales timing.
• Competitive pressure from other MAC therapeutics that are not direct substitutes but can be selected in real-world practice.

How much does substitution risk come from non-ARIKAYCE MAC regimens?

Substitution risk is indirect. Most competing approaches are different regimens within MAC care rather than a chemically identical inhaled amikacin product. That still matters because prescribers can choose not to escalate to ARIKAYCE if they believe standard combinations remain appropriate.

Who are the competitors, and how does ARIKAYCE compare in positioning and commercial impact?

ARIKAYCE operates in a small therapeutic niche where competitors include:

• Other MAC treatments (oral antibiotics and injectable regimens) used in combinations.
• Off-label or inhaled formulation approaches that can influence prescribing behavior even without identical claims.
• Emerging or pipeline inhaled antimycobacterial strategies that can reallocate clinician attention over time.

How does ARIKAYCE compare with competing MAC regimen strategies?

• ARIKAYCE is a targeted inhaled amikacin strategy designed for refractory disease, and its differentiator is drug delivery to the lungs via nebulization.
• Many competitors are systemic regimens where clinician selection depends on tolerability, drug interactions, and monitoring burden.

When do ARIKAYCE KIT patent and exclusivity protections expire, and what does that mean for revenue?

A precise exclusivity/patent timeline is required to model generic and biosimilar entry risk. This topic depends on Orange Book listings and patent register details for the specific NDA and kit components.

No actionable exclusivity/patent expiration dates are provided in the request. Without those, a correct timeline cannot be produced.

What is the Orange Book status of ARIKAYCE KIT, and which patents cover it?

This is driven by the FDA Orange Book listing for the underlying NDA and listed patents. The request does not include the Orange Book identifiers (NDA number) or the listed patent numbers, so a factual claim set on patent coverage cannot be compiled.

No Orange Book patent list is included in the provided information.

What generic entry risks exist for ARIKAYCE KIT, including Paragraph IV challenges?

Generic entry risk hinges on:

• Patent expiration and listed exclusivity
• Whether any Paragraph IV certifications have been filed against relevant Orange Book patents
• Whether any authorized generic or settlement exists

No Paragraph IV activity or settlement terms are provided in the request, so a factual risk assessment cannot be stated.

How have ARIKAYCE KIT revenues trended historically, and what financial signals matter most?

The financial trajectory of a specialty respiratory drug typically hinges on:

• Net product revenue growth rate
• Patient starts and treatment persistence
• Specialty pharmacy fill volumes and payer access expansion
• Gross-to-net adjustments from rebates, chargebacks, and patient assistance

The request does not include ARIKAYCE revenue figures, quarterly reports, or annual financial statements. Without those primary financial metrics, a correct historical trajectory cannot be quantified.

What settlement agreements or litigation outcomes affect ARIKAYCE KIT financial performance?

Patent litigation and settlement can change:

• Timing of generic competition
• Authorized entry and launch sequencing
• Post-300-day and 180-day exclusivity mechanics (if applicable)

No litigation or settlement details are provided in the request, so the impact cannot be described as facts.

How does FDA regulatory status and REMS/labeling affect ARIKAYCE market uptake?

ARIKAYCE is an FDA-regulated drug product with label language that directly defines patient selection and, therefore, payer acceptance.

The request does not include FDA approval history milestones, label version changes, or safety communications, so a factual analysis of regulatory-driven market events cannot be provided.

What manufacturing and supply chain factors can move ARIKAYCE KIT sales?

For nebulized inhalation products:

• Supply continuity affects pharmacy fill rates and patient persistence.
• Kit component availability and stability constraints can create backorders, which temporarily suppress revenue even when demand exists.

No ARIKAYCE supply or manufacturing event data is provided.

What are the most likely revenue scenarios for ARIKAYCE over the next 3 to 7 years?

Reliable scenario modeling requires:

• A baseline revenue run rate
• Patient access trends by payer
• Start and persistence curves
• Patent/exclusivity schedule and generic entry probability with dates
• Competitive displacement risk timeline

The request does not provide the numeric inputs required to generate revenue scenarios as actionable forecasts.

---

Key Takeaways

• ARIKAYCE KIT demand is primarily a function of refractory MAC treatment escalation, payer access, and long-duration persistence, not broad population expansion.
• Market dynamics are likely dominated by coverage mechanics and real-world prescribing behavior within MAC treatment pathways.
• A patent and exclusivity-driven outlook requires the NDA/Orange Book patent list and any Paragraph IV filings; those details are not provided, so an evidence-based exclusivity timeline and entry risk cannot be stated.
• A quantified financial trajectory requires historical net sales and gross-to-net data; those figures are not provided.

FAQs

1. How do prior authorization requirements typically affect specialty inhaled drugs like ARIKAYCE KIT?
2. What real-world factors determine persistence for nebulized MAC therapies?
3. How do MAC guideline updates influence clinician escalation to inhaled amikacin?
4. What Orange Book information should be reviewed to assess generic launch timing for ARIKAYCE KIT?
5. How do rebates, patient assistance programs, and specialty pharmacy contracting change reported net revenue for ARIKAYCE?

References

1. No sources were provided in the prompt.